









Markets
/
Stocks
/
nasdaq-alxo
/

ALX Oncology Holdings Inc

ALXO

2.050USD

-0.010-0.49%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

109.83MMarket Cap

LossP/E TTM



ALX Oncology Holdings Inc

2.050

-0.010-0.49%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of ALX Oncology Holdings Inc

Currency: USD Updated: 2026-02-06

Key Insights

ALX Oncology Holdings Inc's fundamentals are relatively weak, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 58 out of 392 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 3.33.In the medium term, the stock price is expected to trend up.Despite strong stock market performance and technicals over the past month, the fundamentals don't support the current trend.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

ALX Oncology Holdings Inc's Score

Industry at a Glance

Industry Ranking

58 / 392

Overall Ranking

177 / 4521

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Negative

ALX Oncology Holdings Inc Highlights

StrengthsRisks

ALX Oncology Holdings Inc. is a clinical-stage biotechnology company advancing a pipeline of therapies designed to treat cancer and extend patients’ lives. The Company's lead product candidate, evorpacept, is a CD47 blocking therapeutic that combines a high-affinity CD47 binding domain with an inactivated, proprietary Fc domain. It is engaged in focusing on combining evorpacept with anti-cancer antibodies, antibody drug conjugate (ADCs), and PD-1/PD-L1 immune checkpoint inhibitors. Evorpacept is being evaluated across multiple ongoing clinical trials in a range of cancer indications. Its second product candidate is ALX2004, an epidermal growth factor receptor (EGFR)-targeted ADC. ALX2004 comprises an affinity-tuned EGFR antibody backbone engineered for optimal activity as an ADC, a proprietary topoisomerase I inhibitor payload with enhanced bystander effect, and a linker with enhanced stability.

Fairly Valued

The company’s latest PE is -1.02, at a medium 3-year percentile range.

Institutional Buying

The latest institutional holdings are 35.78M shares, increasing 1.57% quarter-over-quarter.

Held by James Simons

Star Investor James Simons holds 164.50K shares of this stock.

Higher Market Activity

The company has more investor interest, with a 20-day turnover ratio of 0.59.

Analyst Rating

Based on 5 analysts

Buy

Current Rating

3.333

Target Price

+65.84%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-02-06

The current financial score of ALX Oncology Holdings Inc is 5.40, ranking 370 out of 392 in the Biotechnology & Medical Research industry. Its financial status is weak, and its operating efficiency is low.

Score

Industry at a Glance

Previous score

5.40

Change



Financials

2.04

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.20

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

4.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

6.75

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.03

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

ALX Oncology Holdings Inc's Company Valuation

Currency: USD Updated: 2026-02-06

The current valuation score of ALX Oncology Holdings Inc is 8.74, ranking 24 out of 392 in the Biotechnology & Medical Research industry. Its current P/E ratio is -1.02, which is -83.77% below the recent high of -0.17 and -363.66% above the recent low of -4.73.

Score

Industry at a Glance

Previous score

8.74

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 58/392

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-02-06

The current earnings forecast score of ALX Oncology Holdings Inc is 8.00, ranking 164 out of 392 in the Biotechnology & Medical Research industry. The average price target is 3.00, with a high of 4.00 and a low of 2.00.

Score

Industry at a Glance

Previous score

8.00

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 5 analysts

Buy

Current Rating

3.333

Target Price

+65.84%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

542

Total

Median

Average

Company name

Ratings

Analysts

ALX Oncology Holdings Inc

ALXO

CRISPR Therapeutics AG

CRSP

argenx SE

ARGX

IQVIA Holdings Inc

IQV

Beigene Ltd

ONC

Intellia Therapeutics Inc

NTLA

...

109

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-02-06

The current price momentum score of ALX Oncology Holdings Inc is 8.50, ranking 63 out of 392 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 2.59 and the support level at 1.34, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

8.54

Change

-0.04

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(1)

Buy(4)

Indicators

Value

Direction

MACD(12,26,9)

0.145

Buy

RSI(14)

70.616

Buy

STOCH(KDJ)(9,3,3)

68.726

Neutral

ATR(14)

0.218

High Vlolatility

CCI(14)

123.414

Buy

Williams %R

28.800

Buy

TRIX(12,20)

1.548

Sell

StochRSI(14)

94.299

Overbought

Moving Average

Sell(0)

Neutral(0)

Buy(6)

Indicators

Value

Direction

MA5

1.934

Buy

MA10

1.733

Buy

MA20

1.549

Buy

MA50

1.426

Buy

MA100

1.494

Buy

MA200

1.061

Buy

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of ALX Oncology Holdings Inc is 10.00, ranking 1 out of 392 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 101.35%, representing a quarter-over-quarter decrease of 1.67%. The largest institutional shareholder is The Vanguard, holding a total of 1.63M shares, representing 3.01% of shares outstanding, with 12.63% decrease in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

VenBio Partners LLC

9.70M

HBM Partners AG

4.50M

+31.31%

Redmile Group, LLC

3.33M

-1.72%

Millennium Management LLC

3.19M

+21.55%

Lightstone Ventures, L.P.

2.95M

Almitas Capital LLC

2.54M

-0.06%

The Vanguard Group, Inc.

Star Investors

1.53M

-4.51%

Two Sigma Investments, LP

1.33M

+12.30%

Acadian Asset Management LLC

1.22M

-3.72%

Risk Assessment

Currency: USD Updated: 2026-02-06

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of ALX Oncology Holdings Inc is 1.89, ranking 273 out of 392 in the Biotechnology & Medical Research industry. The company's beta value is 0.48. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. ALX Oncology Holdings Inc’s latest ESG disclosure leads the Biotechnology & Medical Research industry, indicating outstanding, compliant performance across environmental management, social responsibility, and governance, which may help mitigate overall risk.